Security
ANGO · ANGIODYNAMICS INC
ANGONASDAQCommon stockCurrentCIK 1275187Updated Sep 27, 2026
ANGO price & chart
Loading TradingView…
NASDAQ:ANGO on TradingView ↗About the company
AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients. The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, v isit www.angiodynamics.com.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
SCHEDULE 13G/A - filed by Point72 Asset Management, L.P. regarding ANGIODYNAMICS INC
Other Events
Items 8.01
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
Financials
FY 2026 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 267,163,000Source | 280,144,000Source | 317,671,000Source | 532,637,000Source |
| Property, Plant and Equipment, NetUSD | 27,097,000Source | 32,300,000Source | 35,666,000Source | 44,384,000Source |
| GoodwillUSD | — | — | 0Source | 159,238,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 67,209,000Source | 69,116,000Source | 77,383,000Source | 111,144,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 53,864,000Source | 55,893,000Source | 76,056,000Source | 44,620,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 48,325,000Source | 42,890,000Source | 43,610,000Source | 52,826,000Source |
| Inventory, NetUSD | 52,436,000Source | 62,006,000Source | 60,616,000Source | 55,325,000Source |
| Assets, CurrentUSD | 163,394,000Source | 168,324,000Source | 193,253,000Source | 163,542,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 8,769,000Source | 7,535,000Source | 12,971,000Source | 4,617,000Source |
| Operating Lease, Right-of-Use AssetUSD | 5,053,000Source | 3,850,000Source | 5,804,000Source | 5,113,000Source |
| Other Assets, NoncurrentUSD | 9,463,000Source | 10,404,000Source | 11,369,000Source | 10,676,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 96,338,000Source | 97,174,000Source | 112,085,000Source | 154,341,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 387,000Source | 385,000Source | 385,000Source | 382,000Source |
| Retained Earnings (Accumulated Deficit)USD | -465,939,000Source | -429,197,000Source | -395,204,000Source | -210,855,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 7,675,000Source | -2,023,000Source | -4,365,000Source | -4,723,000Source |
| Stockholders' Equity Attributable to ParentUSD | 170,825,000Source | 182,970,000Source | 205,586,000Source | 378,296,000Source |
| Additional Paid in Capital, Common StockUSD | 636,083,000Source | 621,186,000Source | 610,484,000Source | 599,206,000Source |
| Liabilities and EquityUSD | 267,163,000Source | 280,144,000Source | 317,671,000Source | 532,637,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 74,717,000Source | 76,197,000Source | 91,155,000Source | 83,825,000Source |
| Operating Lease, Liability, CurrentUSD | 1,296,000Source | 1,840,000Source | 1,975,000Source | 1,922,000Source |
| Accounts Payable, CurrentUSD | 31,513,000Source | 33,291,000Source | 37,751,000Source | 40,445,000Source |
| Operating Lease, Liability, NoncurrentUSD | 3,860,000Source | 2,106,000Source | 3,939,000Source | 3,316,000Source |
| Other Liabilities, NoncurrentUSD | 16,305,000Source | 16,904,000Source | 16,078,000Source | 3,350,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 38,909,000Source | 35,518,000Source | 41,098,000Source | 26,617,000Source |
| Deferred Tax Liabilities, NetUSD | 5,230,000Source | 4,058,000Source | 4,812,000Source | 12,765,000Source |
| Long-term DebtUSD | — | — | 0Source | 49,818,000Source |
cash flow · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 13,960,000Source | 9,772,000Source | 10,529,000Source | 11,158,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 5,750,000Source | -23,000Source | -7,894,000Source | 1,299,000Source |
| Increase (Decrease) in InventoriesUSD | -10,047,000Source | 1,347,000Source | 9,410,000Source | 8,198,000Source |
| Deferred Income Tax Expense (Benefit)USD | 143,000Source | -988,000Source | -7,968,000Source | -2,311,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 3,089,000Source | -10,128,000Source | -28,158,000Source | 78,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -5,949,000Source | -10,178,000Source | 123,717,000Source | -9,746,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 2,581,000Source | 4,464,000Source | 2,518,000Source | 3,812,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | 0Source | 1,670,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 564,000Source | -255,000Source | -64,248,000Source | 25,420,000Source |
| Repayments of Long-term DebtUSD | 0Source | 0Source | 50,000,000Source | 45,000,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -2,029,000Source | -20,163,000Source | 31,436,000Source | 15,795,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 53,864,000Source | 55,893,000Source | 76,056,000Source | 44,620,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 405,000Source | 800,000Source | 455,000Source | 342,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 267,000Source | 398,000Source | 125,000Source | 43,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 13,960,000Source | 9,772,000Source | 10,529,000Source | 11,158,000Source |
| Amortization of Intangible AssetsUSD | 10,682,000Source | 10,318,000Source | 13,048,000Source | 18,790,000Source |
| DepreciationUSD | 10,500,000Source | 13,500,000Source | 14,700,000Source | 11,900,000Source |
| Gain (Loss) on Disposition of AssetsUSD | 0Source | 0Source | 54,499,000Source | — |
| Gain (Loss) on Disposition of BusinessUSD | 0Source | 0Source | 54,499,000Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | 0Source | 0Source | — | — |
| General and Administrative ExpenseUSD | 43,691,000Source | 42,092,000Source | 41,164,000Source | 40,003,000Source |
| GoodwillUSD | — | — | 0Source | 159,238,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 159,476,000Source | 14,549,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | 0Source | 0Source | — | — |
| Income Tax Expense (Benefit)USD | 442,000Source | -39,000Source | -7,289,000Source | -1,995,000Source |
| Net Income (Loss) Attributable to ParentUSD | -36,742,000Source | -33,993,000Source | -184,349,000Source | -52,442,000Source |
| Operating ExpensesUSD | 214,819,000Source | 197,659,000Source | 401,632,000Source | 225,427,000Source |
| Operating Lease, ExpenseUSD | 2,345,000Source | 2,632,000Source | 2,549,000Source | 2,694,000Source |
| Other Nonoperating Income (Expense)USD | 3,926,000Source | 4,944,000Source | -817,000Source | -554,000Source |
| Proceeds from Stock Options ExercisedUSD | 0Source | 200,000Source | — | 300,000Source |
income statement · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total RevenueUSD | 320,174,000Source | 292,498,000Source | 303,914,000Source | 338,752,000Source |
| Cost of RevenueUSD | 145,282,000Source | 134,793,000Source | 149,216,000Source | 164,506,000Source |
| Operating Income (Loss)USD | -39,927,000Source | -39,954,000Source | -192,435,000Source | -51,181,000Source |
| Other Nonoperating Income (Expense)USD | 3,926,000Source | 4,944,000Source | -817,000Source | -554,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -36,300,000Source | -34,032,000Source | -191,638,000Source | -54,437,000Source |
| Income Tax Expense (Benefit)USD | 442,000Source | -39,000Source | -7,289,000Source | -1,995,000Source |
| Net Income (Loss) Attributable to ParentUSD | -36,742,000Source | -33,993,000Source | -184,349,000Source | -52,442,000Source |
| Earnings Per Share, BasicUSD per share | -0.88Source | -0.83Source | -4.59Source | -1.33Source |
| Earnings Per Share, DilutedUSD per share | -0.88Source | -0.83Source | -4.59Source | -1.33Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 41,525,697Source | 40,852,564Source | 40,180,925Source | 39,480,367Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 41,525,697Source | 40,852,564Source | 40,180,925Source | 39,480,367Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 10,682,000Source | 10,318,000Source | 13,048,000Source | 18,790,000Source |
| Current Income Tax Expense (Benefit)USD | 299,000Source | 949,000Source | 679,000Source | 316,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 22,955,000Source | 25,800,000Source | 27,712,000Source | 30,873,000Source |
| General and Administrative ExpenseUSD | 43,691,000Source | 42,092,000Source | 41,164,000Source | 40,003,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 159,476,000Source | 14,549,000Source |
| Gross ProfitUSD | 174,892,000Source | 157,705,000Source | 154,698,000Source | 174,246,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -37,787,000Source | -30,172,000Source | -177,314,000Source | -45,240,000Source |
| Interest ExpenseUSD | — | — | -1,614,000Source | 2,702,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | -299,000Source | 978,000Source | — | — |
| Operating ExpensesUSD | 214,819,000Source | 197,659,000Source | 401,632,000Source | 225,427,000Source |
| Operating Lease, ExpenseUSD | 2,345,000Source | 2,632,000Source | 2,549,000Source | 2,694,000Source |
| Research and Development ExpenseUSD | 29,447,000Source | 26,222,000Source | 31,512,000Source | 29,883,000Source |
| Selling and Marketing ExpenseUSD | 113,401,000Source | 103,135,000Source | 102,818,000Source | 104,249,000Source |
Filing attachments
ef20077916_ex99-1.htm · 8-K · 2026-07-14
EX-99.1 2 ef20077916_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability Delivered its seventh consecutive quarter of double-digit Med Tech segment growth and positive adjusted EBITDA LATHAM, N.Y.--(BUSINESS WIRE) - July 14, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restorin…
Read attachment ↗ef20077916_ex99-2.htm · 8-K · 2026-07-14
EX-99.2 3 ef20077916_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Fourth Quarter and Full Year 2026Earnings Results July 14, 2026 Forward looking statements 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expen…
Read attachment ↗ef20069681_ex99-1.htm · 8-K · 2026-04-02
EX-99.1 2 ef20069681_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability Med Tech segment delivered its sixth consecutive quarter of double-digit growth ─────────────────────────────────────────────────────────────────────────────────── Strong adjusted EBITDA Third consecutive quarter the Company raised full year FY 2026 guidance for net sales and Adjusted…
Read attachment ↗ef20069681_ex99-2.htm · 8-K · 2026-04-02
EX-99.2 3 ef20069681_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Third Quarter FY 2026Earnings Results April 2, 2026 Forward looking statements 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, pr…
Read attachment ↗ef20062701_ex99-1.htm · 8-K · 2026-01-14
EX-99.1 2 ef20062701_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 J.P. Morgan 44th Annual Healthcare Conference January 14, 2026 Jim Clemmer, President & CEO Forward looking statements 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, pr…
Read attachment ↗ef20062354_ex99-1.htm · 8-K · 2026-01-06
EX-99.1 2 ef20062354_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability Med Tech segment delivers fifth consecutive quarter of double-digit growth, ─────────────────────────────────────────────────────────────────────────────── Strong adjusted EBITDA; and positive cash flow Three regulatory milestones support Mechanical Thrombectomy portfolio: Modified A…
Read attachment ↗